Sulindac versus piroxicam in the treatment of osteoarthritis

Twenty-nine patients with osteoarthritis of the hip and/or knee(s) were entered into an 8-week, open, parallel group study of sulindac (400 mg daily) and piroxicam (20 mg daily). The results showed that both drugs produced improvements in the patients' overall condition with a trend for sulindac to be superior to piroxicam. There was no difference between the two drugs in terms of adverse reactions. Overall, both drugs proved beneficial and had an acceptable side-effect profile.